Investigating a new dosing method for treating pediatric lupus nephritis
Official title: The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
Funded at Cincinnati Childrens Hosp Med Ctr · NIH-11077820 · Data updated 2026-11-12
This study is looking at how to make treatment better for kids with lupus kidney disease by comparing two ways of giving a medication called mycophenolate mofetil (MMF) to see which one helps their kidneys work better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cincinnati Childrens Hosp Med Ctr NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | July 15, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,167,839 |
| NIH project number | 5R01AR079124-04 |
| Project ID | NIH-11077820 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children diagnosed with proliferative lupus nephritis who are between the ages of 0 and 11.
✕Less likely to help
Patients who do not have lupus nephritis or are older than 11 years may not benefit from this research.
What this research studies
This research focuses on improving the treatment of pediatric proliferative lupus nephritis by comparing two different dosing methods of the medication mycophenolate mofetil (MMF). One method is based on standard weight or body-surface-area calculations, while the other uses a pharmacokinetically-guided approach that tailors the dose to individual patient needs. The study will involve a randomized, double-blind controlled trial over 104 weeks, aiming to determine which method leads to better kidney health outcomes in children. Participants will be monitored for their response to treatment, specifically looking for improvements in kidney function.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for children with lupus nephritis, potentially improving their kidney health and overall quality of life.
How similar studies have gone: Previous research in adults has shown promising results with similar pharmacokinetically-guided dosing approaches, suggesting potential for success in pediatric populations.
Where this research is happening
-
Cincinnati Childrens Hosp Med Ctr
Cincinnati, United States Active
Researchers
- Principal investigator: Brunner, Hermine I — Cincinnati Childrens Hosp Med Ctr
- Study coordinator: Brunner, Hermine I
Related research
Other NIH-funded projects on the same topics.
-
Glycoprotein urine markers that signal lupus nephritis treatment response
A novel test uses urine glycoprotein patterns to show how well lupus nephritis is responding to standard treatment.
-
PTPRS and lupus nephritis: a new target to reduce kidney damage in lupus
Aims to understand how PTPRS contributes to kidney inflammation and scarring in lupus nephritis and explore targeting it to help patients.
-
Sodium’s effect on kidney B cells in lupus kidney disease
This grant explores how high sodium in the kidneys affects B cells in lupus nephritis and whether blocking a key cellular pump could reduce kidney damage.
-
Oral CD11b Activator for Lupus Nephritis
A new oral CD11b activating drug is being explored to help people with lupus nephritis by targeting immune pathways that cause kidney inflammation.
-
Objective classification of lupus nephritis using computer vision
A new computer vision tool uses deep learning to classify lupus nephritis from kidney tissue images to help doctors predict outcomes for patients with lupus.
-
AI-powered look at lupus nephritis in humans and mice
Researchers will use artificial intelligence to compare kidney tissue from people with lupus nephritis to tissue from mouse models, aiming to understand why treatments work differently in humans.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.